PT Kimia Farma (Persero) Tbk (“the Company”) recorded a significant improvement in its financial performance through the third quarter of 2026. In addition to maintaining sales at IDR 7 trillion, the Company posted an operating profit of IDR 227 billion—a 129.31% year-on-year (YoY) increase compared to the IDR 99 billion recorded in the same period the previous year. EBITDA also grew by 32.04% YoY, reaching IDR 503 billion, up from IDR 381 billion in the third quarter of 2025. Meanwhile, the net loss was successfully reduced to IDR 13 billion—an improvement of IDR 221 billion compared to the net loss of IDR 234 billion in the same period the previous year.
These achievements reflect progress in the execution of the Company’s business and financial transformation, specifically through strengthened operational performance, enhanced efficiency, and optimized resource management. The improvements in operating profit and EBITDA are key components of Kimia Farma’s efforts to bolster its business fundamentals and sustain the momentum of its performance recovery. Djagad Prakasa Dwialam, President Director of PT Kimia Farma (Persero) Tbk, stated that the performance through the third quarter of 2026 demonstrates positive developments in the transformation process currently underway. “The Company’s performance through the third quarter of 2026 shows that the turnaround process is progressing in a positive direction. The 129.31% growth in operating profit and 32.04% growth in EBITDA reflect improvements in the fundamentals of our operational performance, as well as the results of ongoing efforts to enhance business efficiency and effectiveness. We will continue to maintain this momentum by strengthening our business fundamentals and ensuring that every step of the transformation delivers a tangible impact on the Company’s sustainability,” said Djagad. Beyond the improvements in operating profit and EBITDA, the Company also succeeded in significantly reducing its net loss. From a net loss of IDR 234 billion in the third quarter of 2025, the figure decreased to IDR 13 billion in the same period of 2026—an improvement of approximately 94.49%.
“This reduction in net loss marks a significant development in Kimia Farma’s transformation journey. Our focus extends beyond short-term financial improvements; we are building a healthier business foundation, strengthening operational discipline, and enhancing the company’s competitiveness to ensure sustainable growth,” added Djagad.
Six Pillars of Transformation to Sustain the Momentum of Improvement
To maintain the sustainability of its performance improvements, Kimia Farma has been—and continues to be—driven by a transformation strategy built on six key pillars: working capital resilience, strengthening human resource (HR) competencies, digitizing business processes, operational efficiency, reinforcing Good Corporate Governance (GCG), and fostering synergy across the Kimia Farma Group. Financially, the company continues to bolster working capital management and liquidity to ensure more effective operational activities. Operationally, the company is driving efficiency and productivity through cost control, optimized asset utilization, and enhanced product portfolio management—aligning offerings with market needs and their contribution to overall business performance. Meanwhile, the digitization of business processes, the enhancement of HR competencies, and the strengthening of corporate governance are integral to building an organization that is more adaptive, productive, and accountable. Furthermore, synergy across the Kimia Farma Group continues to be encouraged to optimize existing capabilities, improve coordination, and create added value for the company as a whole.
Focus for the Fourth Quarter of 2026 and Beyond: Continuing to Strengthen Fundamentals and Resolve Legacy Challenges
As it enters the fourth quarter of 2026, the company remains committed to its transformation of corporate governance and the strengthening of its business fundamentals as its top priorities. Improvements are focused on strengthening internal controls, risk management, disciplined decision-making, and accountability to support a healthier and more sustainable corporate management. In terms of business and finance, the Company continues to enhance working capital and liquidity management, cost control, asset productivity, and the optimization of its product portfolio. These measures are aimed at improving the efficiency and quality of operational performance, while simultaneously strengthening the Company’s competitiveness and foundation for growth. As part of this improvement process, the Company also continues to address historical challenges in a careful and measured manner, guided by applicable regulations and the principles of good corporate governance. Such matters are handled with due regard for the interests of the Company and its shareholders, as well as the sustainability of its operations.
Kimia Farma as the Backbone of National Health Resilience
As part of the Bio Farma Group within the Danantara Indonesia ecosystem, Kimia Farma plays a strategic role as the backbone of national health resilience. Consequently, the Company continues to strengthen business synergies and supply chains to enhance efficiency and ensure the availability of healthcare products and services. This transformation is aimed at building a more resilient business, bolstering the Company’s contribution toward the self-reliance of Indonesia’s pharmaceutical industry, and supporting national health resilience.